Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data

Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data

Abstract Introduction The safety profile of tocilizumab (TCZ) in patients with rheumatoid arthritis (RA) is well established. TCZ was approved to treat giant cell arteritis (GCA) in 2017 in the USA and Europe, and its safety profile in patients with GCA continues to be defined. The objective of this...

Full description

Bibliographic Details
Main Authors: Sara Gale, Huong Trinh, Katie Tuckwell, Neil Collinson, John H. Stone, Khaled Sarsour, Jinglan Pei, Jennie Best, Christine Birchwood, Shalini V. Mohan
Format: Article
Language:English
Published: Adis, Springer Healthcare 2019-02-01
Series:Rheumatology and Therapy
Subjects:
Giant cell arteritis
Rheumatoid arthritis
Rheumatology
Safety
Tocilizumab
Online Access:http://link.springer.com/article/10.1007/s40744-019-0139-5

Internet

http://link.springer.com/article/10.1007/s40744-019-0139-5

Similar Items